AnnMarie Liapakis, MD

• David Mulligan
• Joseph Lim
• Michael Schilsky
• Peter Steven Yoo
• Pramod Mistry
• Sanjay Kulkarni

Digestive System Diseases; Hepatitis Viruses; Transplantation

• Variation in adult living donor liver transplantation in the United States: Identifying opportunities for increased utilizationLentine K, Tanaka T, Xiao H, Bittermann T, Dew M, Schnitzler M, Olthoff K, Locke J, Emre S, Hunt H, Liapakis A, Axelrod D. Variation in adult living donor liver transplantation in the United States: Identifying opportunities for increased utilization Clinical Transplantation 2023, e14924. PMID: 36733213, DOI: 10.1111/ctr.14924.
• Pharmacokinetics and important drug–drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti‐viral therapyCohen E, Liapakis A. Pharmacokinetics and important drug–drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti‐viral therapy Seminars In Dialysis 2018, 32: 141-151. PMID: 30557903, DOI: 10.1111/sdi.12763.
• Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney diseasePoliti M, George N, Li T, Korenblat K, Fowler K, Ho C, Liapakis A, Roth D, Yee J. Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease Pilot And Feasibility Studies 2018, 4: 55. PMID: 29484199, PMCID: PMC5822614, DOI: 10.1186/s40814-018-0251-2.
• Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and CirrhosisLim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z, Group H. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis Clinical Gastroenterology And Hepatology 2018, 16: 1811-1819.e4. PMID: 29306043, PMCID: PMC6034985, DOI: 10.1016/j.cgh.2017.12.037.
• The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ TransplantationLevitsky J, Formica R, Bloom R, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O'Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation American Journal Of Transplantation 2017, 17: 2790-2802. PMID: 28556422, DOI: 10.1111/ajt.14381.
• A New Clinical Paradigm for Hepatitis C End-Stage Renal Disease Patients: Balancing Viral Eradication and Early Kidney TransplantationKulkarni S, Do A, Liapakis A. A New Clinical Paradigm for Hepatitis C End-Stage Renal Disease Patients: Balancing Viral Eradication and Early Kidney Transplantation Internal Medicine Review 2017, 3 DOI: 10.18103/imr.v3i9.570.
• Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal functionSaxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, Terrault NA, HCV‐TARGET. Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function Liver International 2016, 36: 807-816. PMID: 26923436, PMCID: PMC6453817, DOI: 10.1111/liv.13102.
• Diagnosis, Management, and Prevention of Hepatitis B ReactivationLee H, Liapakis A, Lim J. Diagnosis, Management, and Prevention of Hepatitis B Reactivation Current Hepatology Reports 2015, 14: 184-194. DOI: 10.1007/s11901-015-0271-9.
• Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational CohortDo A, Lim J, Liapakis A, Babas G, Caldwell C, Fortune B, Emre S, Kulkarni S, Lempit S, Mistry P, Mulligan D, Rodriguez-Davalos M, Schilsky M, Tichy E, Yoo P, Jakab S. Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational Cohort Gastroenterology 2015, 148: s-1094-s-1095. DOI: 10.1016/s0016-5085(15)33733-1.
• LP02 : C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney diseaseRoth D, Nelson D, Bruchfeld A, Liapakis A, Silva M, Monsour H, Martin P, Pol S, Londoño M, Hassanein T, Zamor P, Zuckerman E, Zhao Y, Wan S, Jackson B, Robertson M, Wahl J, Barr E, Greaves W. LP02 : C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease Journal Of Hepatology 2015, 62: s263-s264. DOI: 10.1016/s0168-8278(15)30156-2.
• Impact of rapid point‐of‐care screening tests for the identification of chronic hepatitis C infectionLiapakis A, Lim JK. Impact of rapid point‐of‐care screening tests for the identification of chronic hepatitis C infection Hepatology 2013, 58: 822-826. PMID: 23744577, DOI: 10.1002/hep.26552.
• Is there clinical utility to IL28B genotype testing in the treatment of chronic hepatitis C virus infection?Liapakis A, Jesudian AB. Is there clinical utility to IL28B genotype testing in the treatment of chronic hepatitis C virus infection? Pharmacogenomics 2012, 13: 1317-1319. PMID: 22966879, DOI: 10.2217/pgs.12.111.
• Telaprevir user's guideLiapakis A, Jacobson I. Telaprevir user's guide Liver International 2011, 32: 17-25. PMID: 22212567, DOI: 10.1111/j.1478-3231.2011.02708.x.
• Telaprevir User’s GuideLiapakis A, Jacobson I. Telaprevir User’s Guide Clinics In Liver Disease 2011, 15: 555-571. PMID: 21867936, DOI: 10.1016/j.cld.2011.05.013.
• Research Highlights: Pharmacogenetics of hepatitis C therapyLiapakis A, Jacobson I. Research Highlights: Pharmacogenetics of hepatitis C therapy Pharmacogenomics 2010, 11: 135-139. PMID: 20136353, DOI: 10.2217/pgs.10.25.
• Brown RS, Liapakis A, Wattacheril JJ. Controversies in Hepatology: The Experts Analyze Both Sides, Chapter- Living Donor Liver Transplant for Acute Liver Failure. Slack Incorporated 2011.Brown RS, Liapakis A, Wattacheril JJ. Controversies in Hepatology: The Experts Analyze Both Sides, Chapter- Living Donor Liver Transplant for Acute Liver Failure. Slack Incorporated 2011.